Buy Avodart, Dutas (Dutasteride) 5-alpha-reductase inhibitor
Cheap qualitative Dutasteride 0.5 mg capsules or tablets online
HOW AND WHERE TO BUY DUTASTERIDE (AVODART) 0.5 MG CAPSULES OR TABLETS ONLINE:
from $0.51 per pill
5% discount coupon: dmeds5
from $0.67 per pill
10% discount coupon: hf-5478
DRUGS FOR HEALTH
from $0.72 per pill
5% discount coupon: A1XKPKC
Absorption: Following administration of a single 0.5 mg dose of a soft gelatin capsule, time to peak serum concentrations (Tmax) of dutasteride occurs within 2 to 3 hours. Absolute bioavailability in 5 healthy subjects is approximately 60% (range: 40% to 94%). When the drug is administered with food, the maximum serum concentrations were reduced by 10% to 15%. This reduction is of no clinical significance.
Distribution: Pharmacokinetic data following single and repeat oral doses show that dutasteride has a large volume of distribution (300 to 500 L). Dutasteride is highly bound to plasma albumin (99.0%) and alpha-1 acid glycoprotein (96.6%).
In a study of healthy subjects (n = 26) receiving dutasteride 0.5 mg / day for 12 months, semen dutasteride concentrations averaged 3.4 ng / mL (range: 0.4 to 14 ng / mL) at 12 months and, similar to serum, achieved steady-state concentrations at 6 months. On average, at 12 months 11.5% of serum dutasteride concentrations partitioned into semen.
Metabolism and elimination: Dutasteride (Avodart) is extensively metabolized in humans. In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes. Both of these isoenzymes produced the 4'-hydroxydutasteride, 6-hydroxydutasteride, and the 6,4'-dihydroxydutasteride metabolites. In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4. Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. In human serum following dosing to steady state, unchanged dutasteride, 3 major metabolites (4'-hydroxydutasteride, 1,2-dihydrodutasteride, and 6-hydroxydutasteride), and 2 minor metabolites (6,4'-dihydroxydutasteride and 15-hydroxydutasteride), as assessed by mass spectrometric response, have been detected. The absolute stereochemistry of the hydroxyl additions in the 6 and 15 positions is not known. In vitro, the 4'-hydroxydutasteride and 1,2-dihydrodutasteride metabolites are much less potent than dutasteride against both isoforms of human 5-alpha-reductase. The activity of 6'-hydroxydutasteride is comparable to that of dutasteride.
Avodart (Dutasteride) and its metabolites were excreted mainly in feces. As a percent of dose, there was approximately 5% unchanged dutasteride (~1% to ~15%) and 40% as dutasteride-related metabolites (~2% to ~90%). Only trace amounts of unchanged dutasteride were found in urine 426 ( < 1%). Therefore, on average, the dose unaccounted for approximated 55% (range: 5% to 97%).
The terminal elimination half-life of dutasteride is approximately 5 weeks at steady state. The average steady-state serum dutasteride concentration was 40 ng / mL following 0.5 mg / day for 1 year. Following daily dosing, dutasteride serum concentrations achieve 65% of steady-state concentration after 1 month and approximately 90% after 3 months. Due to the long half-life of this drug, serum concentrations remain detectable (greater than 0.1 ng / mL) for up to 4 to 6 months after discontinuation of treatment.
Pediatric: Dutasteride pharmacokinetics have not been investigated in subjects younger than 18 years.
Geriatric: No dose adjustment is necessary in the elderly. The pharmacokinetics and pharmacodynamics of dutasteride were evaluated in 36 healthy male subjects aged between 24 and 87 years following administration of a single 5 mg dose of Dutasteride (Avodart). In this single-dose study, this medicine half-life increased with age (approximately 170 hours in men aged 20 to 49 years, approximately 260 hours in men aged 50 to 69 years, and approximately 300 hours in men older than 70 years). Of 2,167 men treated with dutasteride in the 3 pivotal studies, 60% were age 65 and over and 15% were age 75 and over. No overall differences in safety or efficacy were observed between these patients and younger patients.
Gender: Avodart (Dutasteride) is contraindicated in pregnancy and women of childbearing potential and is not indicated for use in other women. The pharmacokinetics of dutasteride in women have not been studied.
Race: The effect of race on dutasteride pharmacokinetics has not been studied.
Renal impairment: The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5 mg dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.
Hepatic impairment: The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because Dutasteride (Avodart) is extensively metabolized, exposure could be higher in hepatically impaired patients.
P450 inhibitors: No clinical drug interaction studies have been performed to evaluate the impact of CYP3A enzyme inhibitors on dutasteride pharmacokinetics. However, based on in vitro data, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.
Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1 ng / mL, 25 times greater than steady-state serum concentrations in humans.
Alpha-adrenergic antagonists: In a single-sequence, crossover study in healthy volunteers, the administration of tamsulosin or terazosin in combination with Avodart (Dutasteride) had no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. Although the effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters was not evaluated, the percent change in DHT concentrations was similar for Avodart alone compared with the combination treatment.
Calcium channel antagonists: In a population pharmacokinetics analysis, a decrease in clearance of dutasteride was noted when coadministered with the CYP3A4 inhibitors verapamil (-37%, n = 6) and diltiazem (-44%, n = 5). In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was coadministered with dutasteride (+7%, n = 4).
The decrease in clearance and subsequent increase in exposure to this medication in the presence of verapamil and diltiazem is not considered to be clinically significant. No dose adjustment is recommended.
Cholestyramine: Administration of a single 5-mg dose of Avodart (Dutasteride) followed 1 hour later by 12 g cholestyramine did not affect the relative bioavailability of dutasteride in 12 normal volunteers.
Digoxin: In a study of 20 healthy volunteers, this drug did not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg / day for 3 weeks.
Warfarin: In a study of 23 healthy volunteers, 3 weeks of treatment with Avodart 0.5 mg / day did not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time when administered with warfarin.
Other concomitant therapy: Although specific interaction studies were not performed with other compounds, approximately 90% of the subjects in the 3 randomized, double-blind, placebo-controlled safety and efficacy studies receiving Avodart (Dutasteride) were taking other medications concomitantly. No clinically significant adverse interactions could be attributed to the combination of Dutasteride and concurrent therapy when this medicine was coadministered with anti-hyperlipidemics, angiotensin-converting enzyme (ACE) inhibitors, beta-adrenergic blocking agents, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase Type V inhibitors, and quinolone antibiotics.
Avodart (Dutasteride) related pharmaceutical drugs and medications
|Trade name of the drug
||Pharmaceutical forms and doses
||Tablets; Oral; Alfuzosin Hydrochloride 10 mg; Dutasteride 0.5 mg
||Capsules; Oral; Dutasteride 0.5 mg; Tamsulosin Hydrochloride 0.4 mg
Buy Avodart (Dutasteride) Online
Avodart prescribing information
Copyright © 2015-2019 Dutasteride.purchasedrugs.biz, a division of Pharma-Doctor.com pharmaceutical network.
Home Page |
Cookies Policy |
Terms of Service |